Nanoparticles and the blood coagulation system. Part II: safety concerns.
Nanoparticles and the blood coagulation system. Part II: safety concerns.
复制标题
DOI：
10.2217/nnm.13.49
复制
发表时间：
2013-06
期刊：
影响因子：
--
通讯作者：
Dobrovolskaia MA
中科院分区：
文献类型：
--
作者：
Ilinskaya AN;Dobrovolskaia MA
根据纳米材料的预期用途，纳米颗粒与血液凝固系统的相互作用可能是有益的或不利的。纳米颗粒可以被设计成促凝血剂或携带凝血起始因子来治疗某些疾病。同样，它们可以被设计成抗凝剂或携带抗凝药物以干预凝血是一个问题的其他病理状况。第一部分概述了凝血系统，并评估了该系统与工程纳米材料之间理想界面的讨论，该部分发表在2013年5月的《纳米医学》杂志上。纳米颗粒的不需要的促凝血和抗凝血性质代表了纳米医学领域中的重要问题，并且经常阻碍许多有前途的工程化纳米载体的开发和向临床的过渡。本部分将重点介绍工程纳米材料对血液凝固系统的不良影响。我们将讨论纳米颗粒的物理化学性质之间的关系（例如，尺寸、电荷和疏水性），其决定了它们对血液凝固系统的负面影响，以便理解如何操纵这些性质可以帮助克服不想要的副作用。
Nanoparticle interactions with the blood coagulation system can be beneficial or adverse depending on the intended use of a nanomaterial. Nanoparticles can be engineered to be procoagulant or to carry coagulation-initiating factors to treat certain disorders. Likewise, they can be designed to be anticoagulant or to carry anticoagulant drugs to intervene in other pathological conditions in which coagulation is a concern. An overview of the coagulation system was given and a discussion of a desirable interface between this system and engineered nanomaterials was assessed in part I, which was published in the May 2013 issue of Nanomedicine. Unwanted pro- and anti-coagulant properties of nanoparticles represent significant concerns in the field of nanomedicine, and often hamper the development and transition into the clinic of many promising engineered nanocarriers. This part will focus on the undesirable effects of engineered nanomaterials on the blood coagulation system. We will discuss the relationship between the physicochemical properties of nanoparticles (e.g., size, charge and hydrophobicity) that determine their negative effects on the blood coagulation system in order to understand how manipulation of these properties can help to overcome unwanted side effects.